A preventive LNP-mRNA vaccine encoding a truncated form of OipA conferred protection against Helicobacter pylori challenge in BALB/c mice
Abstract
Helicobacter pylori (H. pylori) infection is associated with a spectrum of gastric diseases, ranging from chronic atrophic gastritis to gastric ulcers, and potentially gastric cancer. The outer membrane protein of H. pylori plays a significant role in its pathogenicity. Although the global incidence of H. pylori infection has declined in recent years, the rise in antibiotic resistance is far from optimistic, highlighting the urgent need for new prevention strategies. Herein we identified the sequence of outer inflammatory protein A (OipA) in H. pylori using mass spectrometry, then two extracellular functional fragments were selected based on the consistency of B-cell and T-cell epitope scores to construct the truncated OipA antigen (Trunc OipA). Based on this fragment (Trunc OipA), we developed a prophylactic lipid nanoparticles (LNPs) formulated mRNA vaccine targeting OipA. After intramuscular immunization in BALB/c mice, the vaccine induced a strong anti OipA specific humoral response, as well as a mixed T helper cell 1/T helper cell 2 (Th1/Th2) cytokine profile and a moderate increase in the proportion of CD8+ T cells in the spleen. Subsequently, this vaccine reduced the colonization of H. pylori and provided protection at least three months following H. pylori challenge, simultaneously demonstrating no pathological change of organs, or damage to cardiac and kidney function. Overall, these data indicate that the OipA LNP-mRNA vaccine is immunogenic and confers protective immunity in mice for at least three months; however, further optimization is needed before clinical translation.
Related
- Lipid nanoparticle-encapsulated mRNA encoding CagW, a conserved component of the Helicobacter pylori type IV secretion system, protects mice against H. pylori challenge
- Dual-Antigen CCHFV Vaccine Induces Neutralizing Immunity and Protection Against Lethal Challenge
- Interaction with complement factor C1q can contribute to and improve monoclonal antibody-mediated protection against lethal HSV-1 challenge
- Isoindole-benzohydrazide derivative potentiates colistin activity to overcome resistance conferred by MCR-1 variants in Escherichia coli
- Potential mechanisms of Bifidobacterium-mediated synergistic antibiotic eradication of drug-resistant Helicobacter pylori
BibTeX
@article{zhao2026preventive,
title = {{A preventive LNP-mRNA vaccine encoding a truncated form of OipA conferred protection against Helicobacter pylori challenge in BALB/c mice}},
author = {Yuqi Zhao and Ying Zhang and Lei Li and Xiaoya Li and Lingjiao Meng and Kexin Li and Cong Zhang and Dailun Hu and Hongtao Zhang and Lianmei Zhao},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1918356},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1918356},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A preventive LNP-mRNA vaccine encoding a truncated form of OipA conferred protection against Helicobacter pylori challenge in BALB/c mice
AU - Yuqi Zhao
AU - Ying Zhang
AU - Lei Li
AU - Xiaoya Li
AU - Lingjiao Meng
AU - Kexin Li
AU - Cong Zhang
AU - Dailun Hu
AU - Hongtao Zhang
AU - Lianmei Zhao
PY - 2026
DA - 2026/11/04
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1918356
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1918356
AB - Helicobacter pylori (H. pylori) infection is associated with a spectrum of gastric diseases, ranging from chronic atrophic gastritis to gastric ulcers, and potentially gastric cancer. The outer membrane protein of H. pylori plays a significant role in its pathogenicity. Although the global incidence of H. pylori infection has declined in recent years, the rise in antibiotic resistance is far from optimistic, highlighting the urgent need for new prevention strategies. Herein we identified the sequence of outer inflammatory protein A (OipA) in H. pylori using mass spectrometry, then two extracellular functional fragments were selected based on the consistency of B-cell and T-cell epitope scores to construct the truncated OipA antigen (Trunc OipA). Based on this fragment (Trunc OipA), we developed a prophylactic lipid nanoparticles (LNPs) formulated mRNA vaccine targeting OipA. After intramuscular immunization in BALB/c mice, the vaccine induced a strong anti OipA specific humoral response, as well as a mixed T helper cell 1/T helper cell 2 (Th1/Th2) cytokine profile and a moderate increase in the proportion of CD8+ T cells in the spleen. Subsequently, this vaccine reduced the colonization of H. pylori and provided protection at least three months following H. pylori challenge, simultaneously demonstrating no pathological change of organs, or damage to cardiac and kidney function. Overall, these data indicate that the OipA LNP-mRNA vaccine is immunogenic and confers protective immunity in mice for at least three months; however, further optimization is needed before clinical translation.
SN - 1664-3224
ER -